Similar articles

• Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.

  Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV, Saji M, Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Villalona-Calero MA, Shah MH. Lam ET, et al. J Clin Oncol. 2010 May 10;28(14):2323-30. doi: 10.1200/JCO.2009.25.0068. Epub 2010 Apr 5. J Clin Oncol. 2010. PMID: 20368568 Free PMC article. Clinical Trial.
• Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer.

  Fagin JA, Tuttle RM, Pfister DG. Fagin JA, et al. J Clin Endocrinol Metab. 2010 Jun;95(6):2621-4. doi: 10.1210/jc.2010-0800. J Clin Endocrinol Metab. 2010. PMID: 20525911 Free PMC article. No abstract available.
• Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.

  Hong D, Ye L, Gagel R, Chintala L, El Naggar AK, Wright J, Kurzrock R. Hong D, et al. Mol Cancer Ther. 2008 May;7(5):1001-6. doi: 10.1158/1535-7163.MCT-07-2422. Epub 2008 Apr 29. Mol Cancer Ther. 2008. PMID: 18445656
• Targeted molecular therapies in thyroid carcinoma.

  Romagnoli S, Moretti S, Voce P, Puxeddu E. Romagnoli S, et al. Arq Bras Endocrinol Metabol. 2009 Dec;53(9):1061-73. doi: 10.1590/s0004-27302009000900002. Arq Bras Endocrinol Metabol. 2009. PMID: 20126863 Review.
• [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].

  Miller K, Bergmann L, Jäger E, Jakse G, Wirth M, Keilholz U; interdisziplinäre Arbeitsgruppe Nierenzellkarzinom der Deutschen Krebsgesellschaft e.V. (DKG). Miller K, et al. Aktuelle Urol. 2009 Jan;40(1):27-30. doi: 10.1055/s-0028-1098786. Epub 2009 Jan 28. Aktuelle Urol. 2009. PMID: 19177318 German.